SEC Form 4 · accession 0001610717-26-000336
IDEAYA Biosciences, Inc. · IDYA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Briseno Andres Ruiz
Officer — Chief Accounting Officer
Period of report
Jul 7, 2026
Accepted (ET)
Jul 9, 2026 · 4:56 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001676725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 7, 2026 | M | 9,550 | $12.86 | A | 36,016 | D | |
| Common StockF2 | Jul 7, 2026 | S | 9,550 | $40.0137 | D | 26,466 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $12.86 | Jul 7, 2026 | M | 9,550 | D | — | Mar 1, 2032 | Common Stock | 9,550 | 19,200 | D |
Explanation of responses
- F1The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 19, 2025.
- F2This transaction was executed in multiple trades in prices ranging from $40.00 to $40.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3100% of the shares subject to the option is fully vested and exercisable.